Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.

Dutta D, Kamrul-Hasan ABM, Joshi A, Dhall A, Nagendra L, Sharma M

Indian journal of endocrinology and metabolism1 May 2025

PMID40688625PMCIDPMC12274044DOI10.4103/ijem.ijem_366_24PepBankPUB-40688625

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity or diabetes, survodutide 2.4 mg reduced body weight by a greater percentage than placebo in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide 2.4 mg led to more weight loss than placebo in pooled trials.
Peptide
Survodutide
Outcome
DecreasePercent body weight change, 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Mean difference in body weight
−7.79%
2.4 mg vs placebo
Source sentences
Summary
Survodutide at 2.4 mg [MD (mean difference) -7.79% (95% confidence interval [CI]: -11.54, -4.07); I² = 98%; P I² = 96%; P < 0.001] was associated with significantly greater percent reductions in…
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862501
02HumanSystematic reviewEfficacy outcome
In adults with obesity or diabetes, survodutide 3.6 mg reduced body weight by a greater percentage than placebo in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide 3.6 mg led to more weight loss than placebo in pooled trials.
Peptide
Survodutide
Outcome
DecreasePercent body weight change, 3.6 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.6 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Mean difference in body weight
−9.08%
3.6 mg vs placebo
Source sentences
Summary
and 3.6 mg [MD - 9.08% (95% CI: -11.63, -6.54); I² = 96%; P < 0.001] was associated with significantly greater percent reductions in body weight compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862502
03HumanSystematic reviewEfficacy outcome
In adults with diabetes or obesity, survodutide 2.4 mg lowered HbA1c in a meta-analysis of RCTs.
In plain wordsIn adults with diabetes or obesity, survodutide 2.4 mg lowered HbA1c in pooled trials.
Peptide
Survodutide
Outcome
DecreasePercent HbA1c change, 2.4 mg
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Mean difference in HbA1c
−0.88%
2.4 mg
Source sentences
Summary
Survodutide of 2.4 mg was associated with significant HbA1c reduction [MD: -0.88% (95% CI - 1.72, -0.05); I² = 99%; P = 0.040].
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862505
04HumanSystematic reviewEfficacy outcome
In adults with obesity or diabetes, survodutide 2.4 mg reduced absolute body weight by 9.14 kg in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide 2.4 mg reduced body weight by 9.14 kg in pooled trials.
Peptide
Survodutide
Outcome
DecreaseAbsolute body weight change, 2.4 mg
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Absolute body weight reduction
−9.14 kg
2.4 mg
Source sentences
Summary
The corresponding absolute body-weight reduction with survodutide 2.4 mg and 3.6 mg was - 9.14 kg (95% CI: -13.76, -4.53) and - 10.23 kg (95% CI: -15.43, -5.04), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862503
05HumanSystematic reviewEfficacy outcome
In adults with obesity or diabetes, survodutide 3.6 mg reduced absolute body weight by 10.23 kg in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide 3.6 mg reduced body weight by 10.23 kg in pooled trials.
Peptide
Survodutide
Outcome
DecreaseAbsolute body weight change, 3.6 mg
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.6 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Absolute body weight reduction
−10.23 kg
3.6 mg
Source sentences
Summary
The corresponding absolute body-weight reduction with survodutide 2.4 mg and 3.6 mg was - 9.14 kg (95% CI: -13.76, -4.53) and - 10.23 kg (95% CI: -15.43, -5.04), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862504
06HumanSystematic reviewSafety outcome
In adults with obesity or diabetes, survodutide 2.4 mg was associated with more treatment-emergent adverse events than placebo in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide 2.4 mg was linked to more side effects than placebo in pooled trials.
Peptide
Survodutide
Outcome
IncreaseTreatment-emergent adverse events, 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
2.4 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Odds ratio, treatment-emergent AEs
2.93
2.4 mg vs placebo
Source sentences
Summary
Survodutide of 2.4 mg [odds ratio (OR): 2.93 (95% CI: 1.66, 5.18); I² = 0%; P I² = 0%; P < 0.001] was associated with significantly higher treatment-emergent AEs, compared to placebo, although sever…
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862506
07HumanSystematic reviewSafety outcome
In adults with obesity or diabetes, survodutide 3.6 mg was associated with more treatment-emergent adverse events than placebo in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide 3.6 mg was linked to more side effects than placebo in pooled trials.
Peptide
Survodutide
Outcome
IncreaseTreatment-emergent adverse events, 3.6 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
3.6 mg weekly · subcutaneous · 4-11 monthsAs given in this study (human).
Measurements
Odds ratio, treatment-emergent AEs
4.61
3.6 mg vs placebo
Source sentences
Summary
Survodutide of 2.4 mg [odds ratio (OR): 2.93 (95% CI: 1.66, 5.18); I² = 0%; P I² = 0%; P < 0.001] was associated with significantly higher treatment-emergent AEs, compared to placebo, although sever…
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862507
08HumanSystematic reviewSafety outcome
In adults with obesity or diabetes, severe adverse events were not increased with survodutide compared with placebo in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, survodutide did not raise severe side effects compared with placebo in pooled trials.
Peptide
Survodutide
Outcome
No significant changeSevere adverse events
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneous · 4-11 monthsAs given in this study (human).
Source sentences
Summary
although severe AEs were not increased.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862508
09HumanSystematic reviewSafety outcome
In adults with obesity or diabetes, gastrointestinal events were the main adverse events with survodutide and were dose dependent in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, stomach and gut side effects were the most common with survodutide, and rose with dose.
Peptide
Survodutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 4-11 monthsAs given in this study (human).
Source sentences
Summary
Gastrointestinal AEs were the predominant AEs and were dose dependent.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862509
10HumanSystematic reviewSafety outcome
In adults with obesity or diabetes, discontinuation due to adverse events was significantly higher with survodutide and was dose dependent in a meta-analysis of RCTs.
In plain wordsIn adults with obesity or diabetes, more people stopped survodutide because of side effects than stopped comparator treatment, and more so at higher doses.
Peptide
Survodutide
Outcome
IncreaseDiscontinuation due to adverse events
Study
n: not reported in source
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneous · 4-11 monthsAs given in this study (human).
Source sentences
Summary
Treatment discontinuation due to AEs was significantly higher with survodutide and was dose dependent.
2 context sentences(design, population, supporting numbers)
Summary · context
Electronic databases were searched for RCTs involving diabetes and/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo/active comparator in control arm.
Summary · context
Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4-11 months were analyzed.
Report a problemFND-4068862510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.